Big Data: Moving From Artificial Trials To A Smarter Regulatory Process
Executive Summary
This year the EU Big Data Task Force intends to deliver an EU-wide strategy on how big data can be used to support the development and evaluation of new medicines. The recent massive growth of data generated by various technologies, such as ‘omics, portable devices, the internet of things and even social media, gives this task force an urgency for pharma and regulators. Bruno Boulanger discusses the impact this will have on how the pharmaceutical industry gathers and delivers data in the future.